Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tissue plasminogen activator (t-PA) levels in plasma or serum were studied in 416 patients with liver diseases: acute hepatitis (AH, n = 30); fulminant hepatitis (FH, n = 36); chronic inactive hepatitis (CIH, n = 57); chronic active hepatitis (CAH, n = 39); compensated liver cirrhosis (cLC, n = 78); decompensated liver cirrhosis (dLC, n = 84); hepatocellular carcinoma (HCC, n = 64); advanced hepatocellular carcinoma (aHCC, n = 28); and compared with that of a control group (n = 106) of healthy subjects. The t-PA levels showed significant increase in patients with AH, FH, CAH, cLC, dLC and HCC, compared with normal controls. The abnormal rates in t-PA levels (higher than 8.3 ng/ml) for each type of liver diseases were 86.1% in FH, 46.2% in CAH, 50% in cLC, 85.7% in dLC, 67.2% in HCC, and 89.3% in aHCC. t-PA levels tended to be higher in more advanced liver diseases. t-PA levels significantly correlated positively with plasminogen activator inhibitor (PAI-1) in AH, cLC, dLC, HCC and aHCC, and negatively with plasmin alpha 1-plasmin inhibitor complex (PIC), plasminogen (Plg), FDP, AT III and alpha 2-plasmin inhibitor (alpha 2-PI) in dLC, prothrombin time (PT) and fibrinogen (Fbg) in HCC. t-PA levels in patients with FH, CAH and dLC were significantly higher than those in patients with AH, CIH and cLC, respectively. Moreover, the changes of t-PA levels in the clinical courses of various liver diseases revealed that t-PA levels increased sensitively with progression of liver diseases or in advanced liver diseases.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases. 131 84

To evaluate prognostic significance of echogenic lesion within small hepatocellular carcinoma (SHCC, less than or equal to 2 cm in diameter), clinical and pathological findings of 32 cases with SHCC containing echogenic lesion (echogenic SHCC) were compared with those of 55 cases with non-echogenic SHCC. Compared with the non-echogenic SHCC group, the frequency of clinical stage I was significantly higher, and there were significantly more cases with solitary tumor relative to cases with multiple tumors in the echogenic SHCC group. Histologically, the incidence of the HCC composed of well-differentiated tumor cells corresponding to Edmondson's grade I was significantly higher in the echogenic SHCC group than in the non-echogenic SHCC group. Although HCCs tended to become progressively less differentiated with increasing tumor sizes in the both groups, the process of cellular change appeared to proceed more slowly in the echogenic SHCC group. Survival rate after tumor detection was 73% at three years, 56% at five years and 48% at seven years and nine years in the echogenic SHCC group, while it was 46% at three years, 42% at five years and 0% at seven years in the non-echogenic SHCC group. The present results showed that the presence of echogenic lesion within SHCC could be useful prognostic indicator.
 ...
PMID:[Prognostic significance of echogenic lesion within small hepatocellular carcinoma]. 131 33

Of 210 patients with hepatocellular carcinoma (n = 135), metastatic liver cancer (n = 71) and cholangiocarcinoma (n = 4) who underwent intra-arterial infusion of adriamycin and/or mitomycin C oil suspension (ADMOS) and cisplatin, and both regimens, pyogenic liver abscess occurred in seven (3.3%). The percentages of abscess formation in the respective types of liver cancer were 0.8, 7.0 and 25%. These differences among the three types of liver cancer were attributed to the volume of the tumor vascular beds to be embolized, which might determine the relative amount or regional Lipiodol retention in the tumor and normal liver tissue. Four of seven patients with hepatic abscess had received the intra-arterial infusion of ADMOS, and their angiographic findings showed sequential decreases in the vascular beds of the tumor in comparison with those of previous infusion procedures; all had hypovascular liver tumors angiographically. We have never experienced this complication in other treatments such as embolization of the hepatic arteries and intra-arterial infusion of water-soluble anticancer drugs alone. These results suggest that the most important factor leading to abscess formation is the ischemic destruction of the intrahepatic ducts secondary to occlusion of the peribiliary arterial plexus by Lipiodol and/or the direct effects of anticancer drugs on these vessels. To avoid this complication, the volume of Lipiodol used for intraarterial infusion therapy should be carefully determined, especially when the patient has hypovascular tumors of the liver and a history of multiple previous intraarterial infusion procedures of anticancer drug. The use of ADMOS should be avoided in patients with hypovascular tumors of the liver such as secondary deposits and cholangiocarcinoma.
 ...
PMID:[Liver abscess formation after treatment of liver cancer by arterial injection using adriamycin/mitomycin C oil suspension (ADMOS)]. 131 61

Hepatocellular carcinoma epidemiology has undergone great changes in Japan. Life span, new diagnostic procedures and viral infections obtained through intravenous injections have contributed to these changes. The aetiological aspects and clinical features of HCC should be reappraised to account for the current use of techniques such as US and CT in the early diagnosis of HCC. In Japan most HCC seem to be HBV and/or HCV associated whereas small HCC seem to be HCV-associated more so than large HCC. The usual clinical symptoms and signs are somewhat useless and of limited value while the newer techniques permit an early clinical diagnosis of small HCC. This diagnostic advancement has also permitted a remarkable progression in HCC therapy.
 ...
PMID:Present trends in Japan with regard to epidemiology and clinical features of hepatocellular carcinoma. 131 15

Hepatocellular carcinoma is endemic in Africa, where in the incidence of the disease in males ranges from 20-100,000 per annum. The tumor tends to occur at a younger age compared to the age of presentation in Europeans or Chinese. The majority of African patients with HCC are HBsAg positive, but HBsAg is more commonly detected in younger vs older patients. Approximately 30% of patients are anti-HCV positive. Both these chronic virus infections may induce disease via the development of cirrhosis. Other environmental factors including carcinogens such as aflatoxin may act as co-factors. Resection rates for hepatocellular carcinoma are low in this population group, and screening for small tumours is not generally undertaken in Africa.
 ...
PMID:Hepatocellular carcinoma in Africans. 131 16

Human neutrophil-mediated oxidative processes against a human hepatoma cell line, HCC-M, was visualized at the cellular level by using a silicon-intensified target camera and subsequently processing with a computer-assisted digital-imaging processor. Neutrophils were activated by a streptococcal preparation, OK-432. A hydroperoxide-sensitive tracer, dichlorofluorescein diacetate, was loaded in HCC-M and temporal and spatial changes of lipid peroxides in this cell after addition of stimulated neutrophils were analyzed. The luminol-dependent chemiluminescence activity of neutrophils was significantly enhanced and continued for at least 2 hr by stimulation with OK-432, and its activity was shown to be accumulated at the site where a neutrophil attached with HCC-M. The intensity of dichlorofluorescein fluorescence in HCC-M rapidly increased after adding stimulated neutrophils, and their reaction was significantly attenuated by superoxide dismutase. The number of non-viable cells was increased as the dichlorofluorescein fluorescence increase. It is suggested that oxidative stress may play an important role in neutrophil-mediated tumor-cell damage.
 ...
PMID:Visualization of oxidative processes at the cellular level during neutrophil-mediated cytotoxicity against a human hepatoma cell line, HCC-M. 131 29

Ultrasonographic screening and follow-up of patients with chronic liver disease lead to the detection of a large number of small asymptomatic hepatocellular carcinomas, so that the changing appearance of this neoplasm during its natural history has now been recognized. Ultrasonography provides information on shape, echogenicity, growth pattern and vascular involvement of the neoplasm. Three different shapes may be identified, depending upon the size and the invasiveness of the neoplasm: nodular, massive and diffuse. The echogenicity is variable and the tumour mass may appear hypo, hyper or isoechoic in comparison with the surrounding liver tissue. A mixed pattern and/or a hypoechoic ring may also be visualized. A tendency to change from a low echo pattern to a low periphery and finally to a massive pattern with increasing echogenicity has been shown in Japanese patients. The infiltrative growth pattern may be grossly distinguished from the expansive one on the basis of the aspect of the tumour boundary. Vascular invasion is easily recognizable as a mass within a major portal branch or even in the portal trunk. Duplex and color Doppler ultrasonography enable further insights on the vascular alterations related to this neoplasm. Abnormal signals, typical of HCC, are characterized by high-peak with broadening of spectrum. Low impedance continuous signals are less characteristic. Finally, ultra-sound guidance allows puncture of intrahepatic nodules as small as 1cm. The sensitivity of this procedure in the diagnosis of focal liver lesions is very high, varying between 91% and 95% with a specificity of 92%-100%.
 ...
PMID:Ultrasonography and guided biopsy in the diagnosis of hepatocellular carcinoma. 131 77

From 1 January 1983 to 1 January 1988, 38 patients were treated for hepatic cancer in the HEINZ-KALK-Hospital. Thirty-one of these had liver metastases due to gastrointestinal cancer and seven had advanced primary hepatocellular cancer. In all patients more than 50% of the liver volume was involved with the tumour or the metastases. Eleven patients with liver metastases of gastrointestinal cancer (excepting colorectal cancer) were treated by intra-arterial hepatic bolus infusion of 750-1000 mg 5-fluorouracil (5-FU) by selective catheterisation of the hepatic or superior mesenteric artery after puncture of the right or left femoral artery. The median survival was 13.4 months. In seven patients with advanced primary hepatocellular carcinoma the same therapeutic regime was used. The median survival was 10 months. In the 21 patients with disseminated metastases of previously resected colorectal cancer a catheter was inserted into the gastro-duodenal artery and connected to a subcutaneously placed port. Brief infusions of 750-1000 mg 5-FU were administered for 14 days with a day interruption and thereafter 2 month interruption. There were few side effects and 80% of the patients continued to work or carry on a normal life. The median survival was 14.4 months. Based on this experience we consider hepatic chemoinfusion with 5-FU in gastrointestinal cancer and advanced primary hepatocellular carcinoma is capable of improving quality of life and possibly expectancy.
 ...
PMID:Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma. 131 89

Radioimmunoimaging and radioimmunotherapy with radioiodinated anti-(hepatocellular carcinoma ferritin) antibody (131I- or 125I-FtAb) have been applied in patients with primary liver cancer. A total of 41 patients with surgically unresectable hepatocellular carcinoma (HCC) and receiving hepatic artery ligation and cannulation during exploratory laparotomy were treated with this regimen by intrahepatic arterial infusion. Compared with the control group, a decline of serum alpha-fetoprotein (65.7% versus 42.9%) and shrinkage of tumor (68.3% versus 33.9%) were observed in the treated group, and a higher second-look resection rate (31.7% versus 5.1%) and longer survival (1-year: 61.0% versus 37.3%, 3-year: 25.0% versus 6.9%) resulted. The administration of antibody through a hepatic arterial catheter (n = 16) was compared with intravenous injection (n = 17) in terms of the tumor-imaging sensitivity in 33 patients with liver cancer. The results indicated that hepatic arterial infusion was superior to intravenous injection. The sensitivity 7 days after the administration was 100% in the i.a. group and 76.5% in the i.v. group, the uptake ratio of tumor to liver being 1.74 +/- 0.57 in the former and 1.34 +/- 0.29 in the latter. Furthermore, intrahepatic arterial infusion revealed a lower anti-antibody detection rate than intravenous injection (0/14 versus 4/11).
 ...
PMID:Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. 131 55

From 1964 to 1990, 318 cases of primary liver cancer were treated by surgery. Of them, 227 (71.3%) were complicated with cirrhosis to various degrees: mild, moderate and severe. The lesions in the latter group was greater than 10 cm in 3 patients, 5-10 cm in 7 and less than 5 cm in 17. All were confirmed by histopathology to be hepatocellular carcinoma. The method of operation was partial hepatectomy in 23 patients and intra-tumoral absolate alcohol injection supplemented by microwave coagulation in 4. The amount of absolate alcohol ranged from 18 to 30 ml with an average of 24 ml. The chief complications were jaundice and ascites (13 patients--48%) and gastrointestinal hemorrhage (3 patients--11%). Operative mortality was 15% (4/27). The 1-, 3- and 5-year survival rates were 82%, 39% and 10%.
 ...
PMID:[Surgical treatment of primary liver cancer complicated with cirrhosis]. 131 92


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>